Inspire Medical: A Great Story Trading Like It's Already the Sequel

# Inspire Medical: A Great Story Trading Like It's Already the Sequel

Here's a fun exercise: take a stock that just ripped 47% off its lows, popped a beat-and-raise quarter, and boasts 86% gross margins — the kind of number that makes software investors jealous — and ask why its operating income for two straight quarters has been basically zero. That's Inspire Medical Systems right now, and the answer to that question is the whole ballgame.

The rebound is real. So is the confusion underneath it.

INSP roared from the $40s to north of $62 after Q2 numbers came in ahead of expectations — $200.6 million in revenue, gross margins at 85.5%, and management raising full-year 2026 revenue guidance to $950 million–$1.0 billion. The Inspire V system's full U.S. launch and the SleepSync digital platform are doing exactly what they were supposed to do: driving a richer sales mix and giving the bulls a reason to believe the growth story isn't over. Institutional ownership climbed another 3.3 percentage points in August. Short covering, accumulation, the whole nine yards — the tape looks like a stock that found religion.

But strip away the sentiment and look at the income statement, and the picture gets murkier. Revenue was actually down 7.6% year-over-year in Q2 thanks to coding disruptions around CPT 64582 and the now-infamous "-52 modifier" — reimbursement plumbing issues that sound boring until they start eating your top line. More importantly, operating income has printed near-zero for two consecutive quarters (-$1.1 million, then -$0.5 million), a jarring comedown from Q4 2025's $46 million. That's not a rounding error. That's a company whose margin story on paper (gross margin!) hasn't yet translated into an earnings story in practice.

The valuation is pricing a recovery nobody's seen yet.

This is the part that should make you pause before chasing the rally: INSP trades at roughly 40x forward earnings versus 13.5x trailing. That's not a typo — that's the market betting hard that operating leverage snaps back and those near-zero quarters were a blip, not a trend. Meanwhile, the stock is sitting above the Street's own consensus price target of $60.40. When your stock price has outrun the analyst community that's supposed to be cheering you on, that's worth noting, not ignoring.

To be fair, the balance sheet gives you plenty of runway to be patient: $320 million in cash against just $29 million in debt, a current ratio over 8.5x, and free cash flow that re-accelerated sequentially ($14.1 million versus $3.1 million). This isn't a company that needs to raise capital or worry about survival. It's a company that needs to prove its margin story translates into an earnings story — and hasn't yet.

Then there's the GLP-1 elephant in the room.

Every OSA name gets this question now, and Inspire is no exception. Weight-loss drugs are a legitimate long-term threat to the total addressable market for sleep apnea devices, full stop. Management and bulls will point to Inspire V adoption and the newly launched "Project Horizon" initiative as evidence the growth runway is intact regardless — but the scope and capital allocation details on Horizon are still pending, which means the market is being asked to trust the story before seeing the receipts.

Where does that leave you?

This is a hold, not a sale and not a chase. The setup is genuinely two-sided: $58 is the gap-fill/support level worth watching, $64 is the pivot resistance that needs to break decisively before you get aggressive. A close below $58 on volume is your invalidation signal — that's when the "recovery priced but not delivered" thesis starts winning the argument. A clean break above $64 with Q3 operating margin actually recovering above $200.6 million in revenue is when the bulls get their vindication.

Inspire is a genuinely good business wearing a valuation that assumes it's already fixed the thing that's currently broken. Great gross margins don't pay the light bill — operating income does. Until two consecutive quarters of near-zero op income turn into one quarter of real leverage, this stock is a story stock trading like a certainty. Watch the print before you watch the target.